Early antiretroviral treatment shrinks the HIV reservoir in infected infants

November 27, 2019

Starting antiretroviral therapy within hours of birth drastically shrinks the reservoir of HIV virus - an important step in efforts to cure infections - and improves antiviral immune responses in newborns with HIV, shows a two-year study of a unique cohort of ten infants in Botswana. The findings demonstrate that starting treatment earlier in life than current guidelines recommend could substantially improve health outcomes in infants with HIV, who experience irreversible immune damage if left untreated. HIV infections in newborns represent a huge health burden in developing countries; one study estimated that 300 to 500 infants are infected every day in sub-Saharan Africa. Because HIV infection in newborns can lead to rapid and fatal immune deficiency, the World Health Organization recommends that infected newborns receive antiretroviral treatment within weeks of birth. However, adhering to these recommendations can be difficult in low-resource and remote settings. To understand how the timing of antiretroviral therapy affects newborns, Pilar Garcia-Broncano and colleagues studied samples from infants over two years in Botswana, where around 24% of pregnant women are living with HIV. The subjects consisted of ten infected infants who began treatment on average seven hours after birth, ten infected infants who began treatment on average four months after birth, and 54 infants without HIV. The researchers saw that the earliest-treated infants showed a much smaller viral reservoir - the latent pool of the virus that persists throughout life - compared to the second infant group at week 96. Early treatment also granted other benefits to the infants, who showed more functional HIV-specific T cell responses and antiviral responses in the innate immune system. Garcia-Broncano et al. note that follow-up studies of the infant cohort could reveal additional benefits of early antiretroviral treatment that might appear later in life.

American Association for the Advancement of Science

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.